Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
04 Avril 2022 - 10:05PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today that it will issue a press release on its first
quarter 2022 financial results on Tuesday, May 3, 2022 at 7:00 a.m.
ET. Following the release, Teva will conduct a conference call and
live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please dial the following numbers:
United States 1-877-870-9135; Israel 1-809-213-985 or International
+44 (0) 2071 928338; passcode: 8636304.
A live webcast of the call will be available on Teva's website
at: http://ir.tevapharm.com/.
Following the conclusion of the call, a replay of the webcast
will be available within 24 hours on Teva's website or by calling
United States 1-866-331-1332; International +44 (0) 3333 009785;
passcode: 8636304.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general including:
uncertainty regarding the COVID-19 pandemic and the governmental
and societal responses thereto; compliance, regulatory and
litigation matters; other financial and economic risks; and other
factors discussed in our Annual Report on Form 10-K for the year
ended December 31, 2021, including in the sections captioned “Risk
Factors.” Forward-looking statements speak only as of the date on
which they are made, and we assume no obligation to update or
revise any forward-looking statements or other information
contained herein, whether as a result of new information, future
events or otherwise. You are cautioned not to put undue reliance on
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220404005695/en/
IR
Ran Meir (267) 468-4475
Yael Ashman +972 (3) 914 8262
PR
Kelley Dougherty (973) 832-2810
Eden Klein +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024